N/A N=44 Reduction of Endometritis After Cesarean Section With the Routine Use of Methergine
Endometritis
Primary: Endometritis Incidence — 0; 0 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=120 RCT(Randomized Clinical Trial ) of Antibiotic Therapy in Chronic Endometritis
Chronic Endometritis
Primary: The Conversion Rate of CE (From Positive to Negative) — 89.8; 12.7 Percentage of participants
N/A N=120 Endometrial Injury for Unexplained Infertility
Infertility
Primary: Measurement of Uterine Artery Pulsatility Index — 2.40; 2.35 index — p=<0.05
Phase 3 N=349 Does Endometrial Injury Improve Intrauterine Insemination Outcome?
Infertility
Primary: Chemical Pregnancy Rate — 40; 19 participants
N/A N=118 Endometrial Injury and Single Embryo Transfer
Primary Infertility
Primary: Clinical Pregnancy Rate
Phase 2 N=41 Assessing the Endometrial Environment in Recurrent Pregnancy Loss and Unexplained Infertility
Recurrent Pregnancy Loss · Unexplained Infertility
Primary: Abnormal Microbiome Bacterial Sequencing
Phase 3 N=662 Endometrial Safety Study
Postmenopause
Primary: Number of Participants in the DRSP/E2 Group With an Assessment of Endometrial Hyperplasia or Worse at End of Study (EoS) (1 Year of Treatment) — 0 Participants
Phase 2 N=233 The Importance of Anti-anaerobic Therapy for Acute Pelvic Inflammatory Disease (PID)
Pelvic Inflammatory Disease
Primary: Clearance of Anaerobic Organisms From the Endometrium — 14; 18; 7; 1 participants — p=0.046
N/A N=300 Endometriosis and the Appendix - Incidence and Pathologic Analysis
Endometriosis of the Appendix
Primary: Incidence of Endometriosis of the Appendix — 23; 30 Participants — p=0.01
N/A N=56 Enriched Environments in Endometriosis
Endometriosis-related Pain · Endometriosis · Pelvic Pain
Primary: Pain Perception — 7.0; 6.2; 7.2; 5.1 units on a scale
Phase 2 N=75 Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus
Endometrial Adenocarcinoma · Endometrial Adenosquamous Carcinoma · Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation
Primary: Histologic Response in Endometrial Adenocarcinomas of the Uterine Corpus That Are Progesterone Receptor Positive Compared With Those That Are Progesterone Receptor…
Phase 2 N=20 Metformin With the Levonorgestrel-Releasing Intrauterine Device for the Treatment of Complex Atypical Hyperplasia (CAH) and Endometrial Cancer (EC) in Non-surgical Patients
Complex Atypical Hyperplasia · Endometrial Cancer
Primary: Complete Response Rate - 6 Months — 80 percentage of participants
Phase 4 N=24 Clinical Trial Comparing Endometrial Transformation With Subcutaneous Progesterone Versus Intramuscular Progesterone
Reproductive Techniques, Assisted
Primary: Predecidual Transformation — 1; 2; 7; 8 participants — p=0.3395
Phase 2 N=35 Fulvestrant for the Treatment of Recurrent or Metastatic Endometrial Carcinoma.
Endometrial Carcinoma
Primary: Determination (for ITT (Intet-to-Treat Set): Efficacy of a Monthly Administration of Fulvestrant in Patients With Recurrent or Metastatic Endometrial Carcinoma by…
N/A N=93 Reproductive Outcome Affected by Two Adjunctive Treatments in Patients With Severe Intrauterine Adhesions
Asherman's Syndrome
Primary: Number of Participants With Pregnancy in Loop-shaped Intrauterine Device Group and Intrauterine Balloon Group — 12; 22 participants — p=0.009
Phase 4 N=120 The Influence of Adjuvant Medical Treatment of Peritoneal Endometriosis on the Outcome of IVF. A Prospective Randomized Analysis.
Infertility · Endometriosis
Primary: Number of Metaphase II Cells (MII) — 8.2; 8.2 MII cells
Phase 2 N=141 Comparison of Different Doses of Oestrogen Therapy for Preventing Intrauterine Adhesion
Asherman Syndrome
Primary: the AFS Score at Second-look Hysteroscopy — 1.6; 1.9 units on a scale — p=>0.05
Phase 4 N=126 Probiotics as Adjuvant Treatment for Bacterial Vaginosis
Bacterial Vaginosis
Primary: Number of Participants With Related Clinical Signs or Symptoms at Baseline — 63; 63 Participants — p=<0.01
N/A N=23 PREvention of Intrauterine Adhesion After Hysteroscopic Surgery With Novel deGradable Film
Intrauterine Adhesion
Primary: Safety (Adverse Events) — 0 device related adverse event
Phase 2 N=10 A Randomized Pilot Study to Evaluate the Effects of a Short Course of Metformin Versus No Therapy in the Period Prior to Hysterectomy for Grade 1-2 Adenocarcinoma of the Endometrium in Obese Non-Diabetic Women
Adenocarcinoma of the Endometrium
Primary: IHC-based Tissue Markers of Proliferation
Phase 2 N=76 Safety and Efficacy Study of MT-2990 in Women With Endometriosis
Endometrial Related Pain
Primary: Mean Change From Baseline to Week 16 in Nonmenstrual Pelvic Pain Using a Pain Scale Ranges From 0 (None) to 3 (Severe) — -0.28; -0.63 units on a scale
N/A N=34 Uterine Contractions and Mode of Progesterone in Frozen Embryo Transfer (FET) Cycles: Randomized Clinical Trial
Infertility
Primary: Number of Uterine Endometrial Contractions Per Minute — 2.4; 1.4 waves per minute
Phase 4 N=37 Endometrial Markers and Response of Endometriosis Patients to Prolonged GnRH Agonist Prior to IVF
Endometriosis · Infertility
Primary: Patients Who Responded to Controlled Ovarian Hyperstimulation — 7; 5; 3; 5 Participants
N/A N=70 Endometrial Biopsy Instrument Comparison Study
Pain
Primary: Compare Pipelle and Explora Curette Groups With Respect to Patient Perception of Pain Associated With the Procedure as Rated by a 100mm Visual Analog Scale (VAS)…
Phase 2 N=67 Quinagolide Vaginal Ring on Lesion Reduction Assessed by MRI in Women With Endometriosis/Adenomyosis
Endometriosis
Primary: Changes in the Sizes (mm) of Endometrioma, Deep Infiltrating Endometriosis (DIE) and Adenomyosis Lesions Summed by Type on Magnetic Resonance (MR) Images at Cycle 4…
Phase 3 N=29 An Endometrial Cancer Chemoprevention Study of Metformin
Gynecology
Primary: To Evaluate the Participant Body Weight in Pounds (Lbs) — 108.57; 99.3; 101.64; 94.1 lbs — p=0.006
N/A N=204 Lymph Node Mapping in Patients With Endometrial Cancer
Endometrial Cancer
Primary: Negative Predictive Value of Sentinel Lymph Node Prediction of Metastatic Disease — 98.8 percentage of patients
Phase 4 N=44 Resveratrol for Pain Due to Endometriosis
Endometriosis
Primary: Pain Scores Measured by VAS (Visual Analog Scale) at Day 42. — 3.2; 3.9 units on a scale — p=0.7
N/A N=15 Radiofrequency Ablation of Adenomyosis
Adenomyosis
Primary: Post-operative Evidence of Adenomyoma Tissue Ablation Effect by Area (n) as Assessed by Pathological Analysis — 9; 8; 7; 6 treated areas
N/A N=100 Adipocytokines in Endometrial Cancer
Endometrial Cancer · Obesity
Primary: Correlation Between Circulating Levels of These Markers and Demographic Characteristics. — 39; 42; 11; 8 Participants — p=0.026